Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been officially diagnosed with multiple myeloma (a type of blood cancer) according to recognised international standards.
- You are generally able to carry out daily activities with little to no limitation (your doctor rates your physical ability as 0, 1, or in some parts of the study, 2 on a standard scale).
- You are not currently pregnant and do not plan to become pregnant during the study.
- You are willing to sign a consent form showing you understand the study and agree to take part, before any study-related information is collected.
- For some parts of the study: You have already received at least 3 previous rounds of treatment for your myeloma, and completed at least one full cycle of each, unless your cancer got worse during that treatment.
- For some parts of the study: Your myeloma has been confirmed to be getting worse based on your doctor's assessment using recognised guidelines.
- For some parts of the study: Your myeloma can be measured through blood or urine tests showing certain abnormal protein levels, at the time of screening.
- For some parts of the study: Your previous treatments included three specific types of therapy — a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody (confirm with trial site if unsure which medicines these refer to).
- For other parts of the study: Your previous treatments also included a therapy targeting a protein called BCMA, in addition to the three types listed above (confirm with trial site).
- For another part of the study: You are starting a treatment called talquetamab for multiple myeloma that has come back or stopped responding to treatment, and this decision was made separately from the decision to join the study.
Who may not be able to join:
- You are currently pregnant or plan to become pregnant during the study period.
- You have not signed the required consent form before study data collection begins.
- For some parts of the study: You have not had at least 3 previous lines of myeloma treatment (confirm with trial site for exact requirements).
- For some parts of the study: Your myeloma cannot be measured through standard blood, urine, or imaging tests at the time of screening (confirm with trial site).
- For the talquetamab part of the study: Your talquetamab treatment started more than 21 days before you signed the consent form, or is planned to start more than 28 days after screening begins (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Janssen Pharmaceutica N.V., Belgium Clinical Trial, Janssen Pharmaceutica N.V., Belgium
Phone: 844-434-4210
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Overall Response Rate (ORR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.